Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.64 |
| ▸ | PPARG | P37231 | 10/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1868797 | 0.91 | PPARA (0.65) | PPARAPPARGPDE10A | |
| SCHEMBL1870292 | 0.91 | PPARA (0.64) | PPARAPPARG | |
| SCHEMBL1865524 | 0.90 | PPARA (0.60) | PPARAPPARGPDE10AKDM4EALDH1A1 | |
| SCHEMBL12803081 | 0.90 | PPARA (0.63) | PPARAPPARGPDE10A | |
| SCHEMBL1898208 | 0.89 | PPARA (0.62) | PPARAPPARG | |
| SCHEMBL12802359 | 0.87 | PPARA (0.57) | PPARAPPARGPDE10AKDM4EALDH1A1 | |
| SCHEMBL1867551 | 0.83 | ALDH1A1 (0.56) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL1872432 | 0.82 | PPARA (0.49) | PPARAPPARGKDM4EALDH1A1LMNA | |
| SCHEMBL12802902 | 0.82 | PPARA (0.61) | PPARAPPARGPDE10AKDM4EALDH1A1 | |
| SCHEMBL1867356 | 0.81 | PPARA (0.62) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | claimed |
| EP-2567957-A1 | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LIMITED (IN) | 2013-03-13 | — | — | EP | claimed |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | US | claimed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | claimed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | claimed |
| EP-2483266-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-25 | — | — | EP | disclosed |
| EP-2567957-A1 | Compounds for the treatment of dyslipidemia and related diseases | CADILA HEALTHCARE LIMITED (IN) | 2013-03-13 | — | — | EP | disclosed |
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2012-10-04 | — | — | US | disclosed |
| EP-2483266-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Cadila Healthcare Limited (IN) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011051961-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252796-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | PCSK9, APOB, CPT1A | PPARA 132/4885PPARG 122/4885PDE10A 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.